A Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making
|
|
- Anissa Weaver
- 5 years ago
- Views:
Transcription
1 Presenter: Chris Cameron CANNeCTIN November 8, 2013 A Primer on Health Economics & Integrating Findings from Clinical Trials into Health Technology Assessments and Decision Making
2 Acknowledgements Vanier Canada Graduate Scholarships (Vanier CGS) Canadian Institutes of Health Research (CIHR) CANNeCTIN University of Ottawa Dr. George Wells, Dr. Doug Coyle, and Dr. Tammy Clifford Drug Safety and Effectiveness Network (DSEN) University of Ottawa Heart Institute
3 Health Economics General Concepts Economics is the study of unlimited needs/wants constrained by a limited number of resources (scarcity) Choices need to be made For each choice that is made there is an opportunity cost associated with it
4 Opportunity Cost in Health Care Similar principles apply when considering health technologies Since we are not able to pay for all health technologies, we need to make choices In doing so, we need to know whether a health technology is worth the cost
5 Health Economic Evaluation Provide a measure of value for money Comprised of two concepts: 1. Cost 2. Clinical / health effects Systematic way to compare health technologies
6 Decrease in total costs(-) 0 Increase in total costs (+) Comparing Health Technologies Status quo better than Health Technology A? Consider cost effectiveness O? Consider cost effectiveness Health Technology A Better than status quo Reduced clinical benefit (-) 0 Improved clinical benefits (+) O =what health technology is compared to (e.g., status quo)
7 Health Economic Evaluations Typically reported as a ratio (cost effectiveness): Incremental Cost Effectiveness of Health Technology A versus Health Technology B = Total Cost A Total Cost B Effect A Effect B
8 Cost-Effectiveness Analysis Incremental Cost Effectiveness of Health Technology A versus Health Technology B = Total Cost A Total Cost B Effect A - Effect B -In terms of clinically meaningful outcomes e.g., survival, fracture, infection avoided.
9 Cost-Utility Analysis Incremental Cost Effectiveness of Drug A versus Drug B = Total Cost A Total Cost B QALY A - QALY B Drug impacts patients quality of life or meaningful outcomes that in turn affect quality of life
10 What is a Quality Adjusted Life Year (QALY)? Outcome measure that incorporates both quantity of life (mortality) and health-related quality of life (morbidity) Quantity how long person lives Quality factor that represents a preference for a health state one year of perfect health = one QALY one year less than perfect health < one QALY death = zero
11 Cost-Utility Analysis Incremental Cost Effectiveness of Drug A versus Drug B = $50,000 $37, QALYs-0.8 QALYs = $125,000 per QALY gained
12 What Constitutes Good Value for Money? Cost-effectiveness threshold: maximum that a decision maker is willing to pay for one qualityadjusted life Cost-effectiveness threshold is not empirically estimated in Canada range of $20,000-$100,000 per QALY (Canada) range of 20,000 to 30,000 per QALY (United Kingdom) Not a cost-effectiveness threshold per se but rather a range of threshold values that may be considered acceptable depending on the context
13 Value for Money? Incremental Cost $12,500 ICUR= $125,000 per QALY Cost-effectiveness threshold of $50,000 per QALY gained $5,000 ICUR= $25,000 per QALY $2, QALYs gained Net Health Benefit 0.05 QALYs Net Health Benefit QALYs
14 Other Issues to Consider when interpreting Cost per QALY Disease severity (e.g., terminally ill) Benefits in compliance with treatment (difficult to capture) Unmet need Treatment for which limited options are currently available Benefits beyond those to the health care payer (lost productivity, caregiver time) A QALY Is a QALY Is a QALY Or is it?
15 Health Technology Assessment Technology assessment in health care is a multidisciplinary field of policy analysis. It studies the medical, social, ethical, and economic implications of development, diffusion, and use of health technology (International Network of Agencies for Health Technology Assessment)
16 Terminology - HTA, EBM, & CER
17 HTA Products in Canada Single HTA Multi-HTA Time & Effort
18 Health Economic Components Review of Published Economic Studies Critical Appraisal of Manufacturer s Pharmacoeconomic Submission Primary Health Economic Evaluation Budget Impact Analysis
19 Review of Published Economic Studies
20 Review of Submitted Pharmacoeconomic Evaluation Model & Pharmacoeconomic Report
21 Decision Modeling & Primary Economic Evaluation
22 Introduction Self-monitoring of blood glucose (SMBG) has unclear benefits in patients with type 2 diabetes who do not use insulin Significant expenditure on blood glucose test strips Blood glucose test strips are among the top five classes in terms of total expenditure, with costs exceeding those for all oral antidiabetes drugs combined Over 50% is expended on patients who are not using insulin Decisions regarding the prescribing and reimbursement of blood glucose test strips require consideration of both clinical and cost-effectiveness information
23 Methods Incremental cost-utility analysis using United Kingdom Prospective Diabetes Study (UKPDS) Outcome Model Clinical inputs were obtained from a systematic review and meta-analysis of RCTs comparing SMBG with no self-monitoring Costs and utilities were obtained from published sources The perspective of this analysis was that of a Canadian publicly-funded Ministry of Health. Sensitivity analyses were performed to examine robustness of cost-effectiveness results.
24 Clinical Trial Data
25 Clinical Trial Data
26 Base Case Results Cumulative incidence(%) in no selfmonitoring of blood glucose arm Cumulative incidence(%) in self-monitoring of blood glucose arm ARR (%) NNT Myocardial infarction 36.58% 36.21% 0.38% 266 Ischemic heart disease 13.12% 13.04% 0.09% 1,136 Heart Failure 17.64% 17.20% 0.44% 228 Stroke 16.34% 16.14% 0.20% 500 Amputation 3.55% 3.34% 0.21% 467 Blindness 8.69% 8.49% 0.19% 518 End-stage renal disease 2.29% 2.21% 0.08% 1,299
27 Base Case Results (continued) No SMBG SMBG Difference Between SMBG and No SMBG Quality-adjusted life-years gained* Total direct costs [C$]* $27,997 $30,708 $2,711 Incremental cost per QALY gained (ICUR)* $113,643 = difference; ICER = incremental cost-effectiveness ratio; ICUR = incremental cost-utility ratio; QALY = quality-adjusted life-year; SMBG = self-monitoring of blood glucose. *Discounted at 5% per year. Cost in $C per incremental life-year gained. Cost in $C per incremental quality-adjusted life-year gained.
28 Sensitivity Analysis Reference Case Lower limit of 95% CI for WMD in A1c from 7 RCTs ( A1c=-0.39%) Upper limit of 95% CI for WMD in A1c from 7 RCTs ( A1c=-0.15%) Price per test strip reduced by 25% (C$0.55/strip) Price per test strip reduced by 50% (C$0.36/strip) Price per test strip reduced by 75% (C$0.18/strip) History of diabetes-related complications reflective of patients in DICE study and Canadian diabetes atlases SMBG <1/day, ( A1C=-0.20%; frequency= 0.77 SMBG/day) SMBG 1-2/day, ( A1C=-0.26%; frequency= 1.46 SMBG/day) SMBG >2/day, ( A1C=-0.47%; frequency= 3.5 SMBG/day) Baseline A1c< 8.0% (WMD in A1C%=0.16%, Baseline A1C=7.5%) Baseline A1c, 8.0 to 10.5% (WMD in A1C%=0.30%, Baseline A1C=8.7%) Patients using OAD(s) Patients using diet only therapy ICUR (C$/QALY) $113,643/QALY $77,706/QALY $189,376/QALY $86,129/QALY $58,615/QALY $31,101/QALY $89,656/QALY $81,654/QALY $122,416/QALY $169,120/QALY $213,503/QALY $94,443/QALY $91,724/QALY $292,144/QALY
29 Primary Economic Evaluation Blood Glucose Test Strips Over $330 million expended annually 50% is for patients not using insulin Top five class in terms of total expenditure in drug plans ~ $1/day in patients not using insulin Modest clinical benefits in patients not using insulin in non-industry sponsored RCTs Frequent use (>1 per day) not cost-effective in patients not using insulin - incremental cost per QALY of $113,643 per QALY Reduced price of strips or frequency (e.g., 1 or 2 per week) would improve cost-effectiveness
30 Cost effectiveness vs Budget Impact Analysis Cost effectiveness helps us assess whether a health technology is worth the cost provides good value for money Cost effectiveness does not provide information on affordability, i.e., can we afford it A health technology might be cost effective but the financial impact to a drug plan may be such that it cannot list the health technology Affordability decisions are made by the participating decision makers based on their budgets and priorities
31 Cost effectiveness vs Budget Impact Analysis BIA CEA Question Is it affordable? Is it good value for money? Goal Plan financial impact Economic efficiency (cost containment) (max. health with resources) Unit Entire Population Individual Scope of Costs Narrow perspective (decision-maker costs) Usually broader (health system costs) Health Excluded Outcomes Included Measure Total expenditure ($) Incr. cost per unit of outcome Market dynamics Usually included Time Horizon Usually short (1 5 years) Usually not modeled Usually longer (lifetime?)
32 Budget Impact Analysis: Can we afford not to?
33 Rising Costs of Test Strips
34 Budget Impact of Test Strips
35 Could the money be better spent? 2,200 nurses OR The >$150 million spent annually on blood glucose test strips among patients with type 2 diabetes who are not using insulin could be used to pay for 2,800 dieticians/ nutritionists OR Universal coverage of insulin for all patients with type 1 diabetes in Canada.. and then some. OR All oral Diabetes medication
36 Primary Economic Evaluation & Budget Impact Example
37 Opportunities for enhancing the role of Health Economic Evaluation and HTA in Canada Proximity to Decision Application of payer-specific data Opportunity to integrate HTAs Larger role for sub-group analysis Measure impact of HTAs
38 Proximity to Decision Evidence Generation & Synthesis Decision Making globalize the evidence, localize the decision HTA Report & Decision HTA Report & Recommendation HTA Report
39 Payer-specific Data Payer specific prices Incorporate local clinical/epidemiological data into HTA More accurate estimates of budget impact Contextual issues
40 # of disease areas considered simultaneously Integrating Health Technology Assessment(s) vs. One-off HTA(s) # of health technologies considered simultaneously Assessment of one technology in one disease area Assessment of multiple technologies in one disease area Assessment of one technology in multiple disease areas Assessment of multiple technologies in multiple disease areas
41 More seamless integration of evidence along the continuum Seamless integration of network metaanalysis with economic analysis Value-based pricing Managed entry agreements Research Prioritization
42 Enhanced role of sub-group analysis Studies typically report mean or average effect estimates. However, there are individuals on both sides on the mean those who benefit more and those who benefit less (in some cases those who don t benefit at all).
43 Conveying Opportunity Costs of Decisions 2,200 nurses OR The >$150 million spent annually on blood glucose test strips among patients with type 2 diabetes who are not using insulin could be used to pay for 2,800 dieticians/ nutritionists OR Universal coverage of insulin for all patients with type 1 diabetes in Canada.. and then some. OR All oral Diabetes medication
44 Current Challenges with applying Health Economic Evaluation and HTA in Canada Health economics capacity in Canada Issues not captured in a QALY Prioritization of HTA Topics & Level of effort of Health Economic Evaluation Perspective of HTA Coordination of HTA & Health Economic Evaluations in Canada
45 Decision Modeling & Health Economics Capacity in Canada Expertise in Decision Modeling & Health economics limited in Canada Government & Quasi- Government Recruitment and retention is a challenge in Canada Capacity within HTA units often requires a blend of internal health economist(s) expertise and external contractors Universities Healthcare Consulting Pharmaceutical & Biotech Sector Insurance Industry
46 Time & Effort Prioritization of HTA s and level of effort devoted to Health Economic component Devices Drugs Big Ticket Health Technologies Primary Economic Evaluation & Budget Impact Analysis Procedures Prioritization Criteria Small Ticket Health Technologies Critical Appraisal of Pharmacoeconomic Submission (if applicable) Review of Published Economic Studies and/or rapid budget impact analysis
47 Incorporating items not captured in a QALY Disease severity (e.g., terminally ill) Benefits in compliance with treatment (difficult to capture) Unmet need Treatment for which limited options are currently available Benefits beyond those to the health care payer (lost productivity, caregiver time) A QALY Is a QALY Is a QALY Or is it?
48 Incorporating elements not captured in QALYs
49 Emerging Approaches for formally incorporating these elements
50 Breaking the silos- Enhanced Pan-Canadian Coordination - Budget impact/affordability - Price Negotiation - Managed Entry Agreements - Efficacy versus Tx - Cost-effectiveness versus Tx Other Health Technologies? - Efficacy versus placebo - Safety
51 Purchasing & Price Negotiation Power
52 Perspective of Evaluation Payer Considerations Health System or Societal Considerations - 2,000 new taxi cabs licences In New York City - Generate one time $ 1 Billion US - Catch taxi quicker but in taxi longer - $500 million a year in lost time
53 Summary & Conclusions Clinical trial and epidemiological data form the foundation for health economic evaluations Health economics is an essential component of HTA There are several health economic methodologies that are applicable for decision making There are opportunities for improving the application of health economic evaluation and HTA in Canada There are also challenges but these challenges are not insurmountable
54 Questions?
55 What is a network meta-analysis?
1. Comparative effectiveness of liraglutide
Cost-effectiveness of liraglutide (Victoza ) for the treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. The NCPE has issued a recommendation regarding
More informationUsing Health Economics to Inform the Development of Medical Devices. Matthew Allsop MATCH / BITECIC
Using Health Economics to Inform the Development of Medical Devices Matthew Allsop MATCH / BITECIC Overview Background to MATCH Overview of health economics in product development Concepts relating to
More informationCost-effectiveness of Obinutuzumab (Gazyvaro ) for the Treatment of Follicular Lymphoma
Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the Treatment of Follicular Lymphoma The NCPE has issued a recommendation regarding the cost-effectiveness of obinutuzumab (Gazyvaro ). Following NCPE
More informationPharmacoeconomics: from Policy to Science. Olivia Wu, PhD Health Economics and Health Technology Assessment
Pharmacoeconomics: from Policy to Science Olivia Wu, PhD Health Economics and Health Technology Assessment Potential conflicts of interest - none 2 Pharmacoeconomics: from policy to science - Why the need
More informationNICE Guidelines for HTA Issues of Controversy
NICE Guidelines for HTA Issues of Controversy Mark Sculpher, PhD Professor of Health Economics University of York, UK LMI, Medicines Agency in Norway and the Norwegian Knowledge Centre for the Health Services:
More informationEconomic and societal impact of direct-acting antiviral therapy in Hepatitis C Zoltán Kaló
Economic and societal impact of directacting antiviral therapy in Hepatitis C Zoltán Kaló Professor of Health Economics ISPOR 19th Annual European Congress November 2 nd 2016 ATHCV16099925102016 Concerns
More informationCombination therapy compared to monotherapy for moderate to severe Alzheimer's Disease. Summary
Combination therapy compared to monotherapy for moderate to severe Alzheimer's Disease Summary Mai 17 th 2017 Background Alzheimer s disease is a serious neurocognitive disorder which is characterized
More informationCost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy
Cost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy The NCPE has issued a recommendation regarding the cost-effectiveness
More informationOHTAC Recommendation: Twenty-Four-Hour Ambulatory Blood Pressure Monitoring in Hypertension. Ontario Health Technology Advisory Committee
OHTAC Recommendation: Twenty-Four-Hour Ambulatory Blood Pressure Monitoring in Hypertension Ontario Health Technology Advisory Committee May 2012 Background Hypertension in Canada Hypertension occurs when
More informationSummary. Table 1 Blinatumomab administration, as per European marketing authorisation
Cost-effectiveness of blinatumomab (Blincyto ) for the treatment of relapsed or refractory B precursor Philadelphia chromosome negative acute lymphoblastic leukaemia in adults. The NCPE assessment of blinatumomab
More informationCost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia
Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ). Following NCPE assessment of the applicant
More informationCost-effectiveness of Daratumumab (Darzalex ) for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.
Cost-effectiveness of Daratumumab (Darzalex ) for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma. The NCPE has issued a recommendation regarding the cost-effectiveness of
More informationSummary 1. Comparative effectiveness of ataluren Study 007
Cost-effectiveness of Ataluren (Transarna TM ) for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophy gene in ambulatory patients aged 5 years and older The
More informationCost effectiveness of
Cost effectiveness of brentuximab vedotin (Adcetris ) for the treatment of adult patients with relapsed or refractory CD30 positive Hodgkin Lymphoma who have failed at least one autologous stem cell transplant.
More informationThe long-term cost-effectiveness of bariatric surgery for the treatment of severe obesity: a cost utility analysis from a societal perspective
The long-term cost-effectiveness of bariatric surgery for the treatment of severe obesity: a cost utility analysis from a societal perspective Presented By: Erica Lester MD MSc Disclosure I have no actual
More informationAbout the National Centre for Pharmacoeconomics
Cost-effectiveness of mannitol dry powder for inhalation (Bronchitol ) for the treatment of adult patients with cystic fibrosis as an add-on therapy to best standard of care. The NCPE has issued a recommendation
More informationPanel Value Frameworks for Cancer Therapies: Are they Useful in the Context of Canadian Health Technology Assessments and Reimbursement Decisions?
Panel Value Frameworks for Cancer Therapies: Are they Useful in the Context of Canadian Health Technology Assessments and Reimbursement Decisions? 2017 CADTH Symposium Ottawa, April, 24th, 2017 Reiner
More informationCost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma.
Cost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma. The National Centre for Pharmacoeconomics (NCPE) has issued a
More informationSummary Background 1. Comparative effectiveness of ramucirumab
Cost-effectiveness of ramucirumab (Cyramza ) for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression following previous treatment
More informationCost Effectiveness of canagliflozin (Invokana )
Cost Effectiveness of canagliflozin (Invokana ) for adults with type 2 diabetes mellitus to improve glycaemic control as monotherapy or add-on therapy with other anti-hyperglycaemic agents including insulin,
More informationType of intervention Secondary prevention and treatment; Other (medication coverage policy design).
Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes Rosen A B, Hamel M B, Weinstein M C, Cutler D M, Fendrick A, Vijan S Record Status
More informationCancer Immunotherapy from the Health Technology Assessment (HTA) and Payer Perspectives
BBS PSI Scientific Meeting: Empower the immune system to fight cancer Cancer Immunotherapy from the Health Technology Assessment (HTA) and Payer Perspectives Fred Sorenson, Xcenda Disclaimer and Acknowledgements
More informationBackground Comparative effectiveness of nivolumab
NCPE report on the cost effectiveness of nivolumab (Opdivo ) for the treatment of locally advanced or metastatic squamous non-small cell lung cancer after prior chemotherapy in adults. The NCPE has issued
More informationCost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma
Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma The NCPE has issued a recommendation regarding the cost-effectiveness of obinutuzumab (Gazyvaro ). Following
More informationEconomic Evaluation. Introduction to Economic Evaluation
Economic Evaluation Introduction to Economic Evaluation This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of
More informationDrugs for Rare Disorders
Drugs for Rare Disorders A CASE FOR NATIONAL PHARMACARE THAT LEAVES NO ONE BEHIND Disclosures WIDOWER WHOSE SPOUSE DIED WITHOUT A DIAGNOSIS FATHER OF AN ADULT CHILD WITH A RARE DISORDER CO-FOUNDER & PRESIDENT,
More informationEconomic Analyses in Clinical Trials
Economic Analyses in Clinical Trials Natasha Leighl (and Nicole Mittmann) Committee on Economic Analysis, NCIC CTG Natasha.Leighl@uhn.on.ca; Nicole.Mittmann@sunnybrook.ca Financial Disclosures Research
More information1. Comparative effectiveness of vedolizumab
Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
More informationSummary 1. Comparative effectiveness
Cost-effectiveness of Sacubitril/Valsartan (Entresto) for the treatment of symptomatic chronic heart failure in adult patients with reduced ejection fraction. The NCPE has issued a recommendation regarding
More informationCost-Utility Analysis (CUA) Explained
Pharmaceutical Management Agency Cost-Utility Analysis (CUA) Explained Cost-Utility Analysis (CUA) at PHARMAC Questions and Answers go to page 9 >> This document explains the process that PHARMAC generally
More informationWhat does it mean for innovative technologies/medicines? Health economic evaluations and their role in health care decision making.
Health economic evaluations and their role in health care decision making. Lieven Annemans Ghent University Lieven.annemans@ugent.be December 204 2 Health expenditure is recognised as growthfriendly expenditure.
More informationHow to evaluate the economic impact of interventions I: introduction and costing analyses
How to evaluate the economic impact of interventions I: introduction and costing analyses Raymond Hutubessy Initiative for Vaccine Research (IVR), Geneva, Switzerland Mark Jit WHO consultant, Health Protection
More informationBackground Comparative effectiveness of ibrutinib
Cost effectiveness of ibrutinib (Imbruvica ) in the treatment of patients with chronic lymphocytic leukaemia who have received 1 prior therapy, or as a first-line treatment in the presence of del(17p)
More informationCost-effectiveness of mepolizumab (Nucala ) as an add-on treatment for severe refractory eosinophilic asthma in adult patients.
Cost-effectiveness of mepolizumab (Nucala ) as an add-on treatment for severe refractory eosinophilic asthma in adult patients. The NCPE has issued a recommendation regarding the cost-effectiveness of
More informationThe Cost Effectiveness of Omacor post-myocardial infarction in the Irish Healthcare Setting
The Cost Effectiveness of Omacor post-myocardial infarction in the Irish Healthcare Setting April 2013 1. Omacor is a concentrated preparation of omega-3-acid ethyl esters that contains 46% eicosapentaenoic
More informationBest Practices for Specialty Pharmacy Usage Management. Neil S. Shah, PharmD Specialty Pharmacist, Blue Cross Blue Shield of NC
Best Practices for Specialty Pharmacy Usage Management Neil S. Shah, PharmD Specialty Pharmacist, Blue Cross Blue Shield of NC Overview Provide a background to specialty pharmacy Identify key industry
More informationThe cost of cancer treatment
The cost of cancer treatment Lieven Annemans Ghent University Lieven.annemans@ugent.be January 2016 What s the problem? those prices are too high the budgets will explode these drugs offer survival benefit
More informationCost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout
Cost-effectiveness of lesinurad (Zurampic ) for the treatment of adult patients with gout The NCPE has issued a recommendation regarding the cost-effectiveness of Lesinurad (Zurampic ) in combination with
More informationIntroduction to Cost-Effectiveness Analysis
Introduction to Cost-Effectiveness Analysis Janie M. Lee, MD, MSc RSNA Clinical Trials Methodology Workshop January 13, 2016 Why is Clinical Research Important to Radiology? Radiology currently occupies
More informationCost-effectiveness of evolocumab (Repatha ) for primary hypercholesterolemia and mixed dyslipidemia.
Cost-effectiveness of evolocumab (Repatha ) for primary hypercholesterolemia and mixed dyslipidemia. The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ) Following
More informationEvidence based assessment of the value of innovation: pricing solutions and prospects
Evidence based assessment of the value of innovation: pricing solutions and prospects Karl Claxton 7/11/2017 How much can we pay for innovation? Cost Price > P* 60,000 30,000 per QALY Cost-effectiveness
More information2/20/2012. New Technology #1. The Horizon of New Health Technologies. Introduction to Economic Evaluation
Introduction to Economic Evaluation Sean D. Sullivan, PhD Professor and Director Pharmaceutical Outcomes Research and Policy Program University of Washington The Horizon of New Health Technologies Diagnostics:
More informationMaking Economic Evaluation Fit for Purpose to Guide Resource Allocation Decisions
Making Economic Evaluation Fit for Purpose to Guide Resource Allocation Decisions Mark Sculpher, PhD Professor of Health Economics Centre for Health Economics University of York, UK Outline Policy context
More informationSubject: Canadian Diabetes Association Feedback on New Drugs for Type 2 Diabetes: Second-Line Therapy: A Therapeutic Review Update
February 3, 2017 Canadian Agency for Drugs and Technologies in Health (CADTH) 865 Carling Avenue, Suite 600 Ottawa, Ontario K1S 5S8 Subject: Canadian Diabetes Association Feedback on New Drugs for Type
More informationCost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin
CMAJ Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without insulin Chris Cameron MSc, Doug Coyle MSc PhD, Ehud Ur MD, Scott Klarenbach MD MSc
More informationSetting The setting was secondary care. The economic study was carried out in Sweden.
Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study Borgstrom F, Johnell O, Kanis J A, Oden A, Sykes D, Jonsson B Record Status This
More informationHealth Economics 101: PPI prescriptions in the Emergency Room
: PPI prescriptions in the Emergency Room Canadian Optimal Medication Prescribing & Utilization Service (COMPUS) Presented by: Chris Cameron October 26, 2007 What is Health Economics? Health economics
More informationCost-effectiveness of osimertinib (Tagrisso )
Cost-effectiveness of osimertinib (Tagrisso ) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung
More informationBack to the future: should we live in a post-qaly world?
Back to the future: should we live in a post-qaly world? Moderator: John Spoors, Senior Analytical Lead, NHS By Ad England Rietveld john.spoors@nhs.net RJW&partners Presenters: Andrew Walker Ad Rietveld
More informationSummary 1. Comparative effectiveness of sapropterin dihydrochloride
Cost-effectiveness of sapropterin dihydrochloride (Kuvan ) for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown
More informationClopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K
Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis Schleinitz M D, Weiss J P, Owens D K Record Status This is a critical abstract of an economic evaluation
More informationIn keeping with the Scottish Diabetes Group criteria, use should be restricted to those who:
Advice Statement 009-18 July 2018 Advice Statement What is the clinical and cost effectiveness of Freestyle Libre flash glucose monitoring for patients with diabetes mellitus treated with intensive insulin
More informationThe HTA challenge of medical device assessment: The perspective of assessor
The HTA challenge of medical device assessment: The perspective of assessor Rod Taylor Associate Professor in Health Services Research & Scientific Director of Peninsula Clinical Trials Unit Peninsula
More informationCost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD)
Cost-effectiveness of tolvaptan (Jinarc ) for the treatment of autosomal dominant polycystic kidney disease (ADPKD) The NCPE has issued a recommendation regarding the cost-effectiveness of tolvaptan (Jinarc
More informationEarly release, published at on December 21, Subject to revision.
Early release, published at www.cmaj.ca on December 21, 2009. Subject to revision. Research Cost-effectiveness of self-monitoring of blood glucose in patients with type 2 diabetes mellitus managed without
More information5 $3 billion per disease
$3 billion per disease Chapter at a glance Our aim is to set a market size large enough to attract serious commercial investment from several pharmaceutical companies that see technological opportunites,
More informationLong-Term Cost-effectiveness of Saxagliptin for the Treatment of Type 2 Diabetes in South Africa
Long-Term Cost-effectiveness of Saxagliptin for the Treatment of Type 2 Diabetes in South Africa Deon Olivier October 2012 1 Introduction Saxagliptin is a DPP-4 inhibitor for the treatment of type 2 diabetes
More informationInterpreting Cost-Effectiveness Analyses in the Context of Product Listing Agreements: NIHB s Reanalysis of CADTH s Hepatitis C Therapeutic Review
Interpreting Cost-Effectiveness Analyses in the Context of Product Listing Agreements: NIHB s Reanalysis of CADTH s Hepatitis C Therapeutic Review Andrew Portolesi, Biostatistician, Non-Insured Health
More informationCost-effectiveness of apremilast (Otezla )
Cost-effectiveness of apremilast (Otezla ) alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs) for the treatment of active psoriatic arthritis in adult patients who have had an
More informationHealth technology The use of the antihypertensive drug losartan for the prevention of stroke.
Cost effectiveness of losartan in patients with hypertension and LVH: an economic evaluation for Sweden of the LIFE trial Jonsson B, Carides G W, Burke T A, Dasbach E J, Lindholm L H, Dahlof B Record Status
More informationCADTH SYMPOSIUM 2016 Scott Gavura, Director, Provincial Drug Reimbursement Programs
Cancer Drug Funding Sustainability: From Recommendations to Action CADTH SYMPOSIUM 2016 Scott Gavura, Director, Provincial Drug Reimbursement Programs Contributing authors Provincial Drug Reimbursement
More informationCost-effectiveness of elosulfase alfa (Vimizim ) for the treatment of Morquio A Syndrome in patients of all ages.
Cost-effectiveness of elosulfase alfa (Vimizim ) for the treatment of Morquio A Syndrome in patients of all ages. The NCPE has issued a recommendation regarding the cost-effectiveness of elosulfase alfa
More informationSummary A LOOK AT ELAGOLIX FOR ENDOMETRIOSIS JULY 2018
JULY 2018 WHAT IS ENDOMETRIOSIS? Endometriosis is a chronic gynecological condition with symptoms that include painful menstrual periods, nonmenstrual pelvic pain, and pain during intercourse, as well
More informationFood for thought. Department of Health Services Research 1
Food for thought Suppose you have been asked to undertake an economic evaluation of the costs and effects on the Fall prevention program Identify the range of different costs that you might wish to include
More informationUNIVERSITY OF CALGARY. Cost-effectiveness of chest x-ray screening for diagnosis and treatment of inactive. Dina Avalee Fisher A THESIS
UNIVERSITY OF CALGARY Cost-effectiveness of chest x-ray screening for diagnosis and treatment of inactive pulmonary tuberculosis in a high-incidence country by Dina Avalee Fisher A THESIS SUBMITTED TO
More informationManufacturer Comments Clinical Evidence Review Report and Supplemental Update and Pharmacoeconomic Review Report
Manufacturer Comments Clinical Evidence Review Report and Supplemental Update and Pharmacoeconomic Review Report Drug Product Generic name (Brand name) Manufacturer (Distributor if applicable) Alzheimer
More informationSetting The setting was unclear. The economic study was conducted in Switzerland.
Health-economic comparison of continuous subcutaneous insulin infusion with multiple daily injection for the treatment of Type 1 diabetes in the UK Roze S, Valentine W J, Zakrzewska K E, Palmer A J Record
More informationIntroduction. Summary A LOOK AT CAR-T THERAPIES MARCH 2018 LEUKEMIA AND LYMPHOMA CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY
MARCH 2018 Introduction LEUKEMIA AND LYMPHOMA This review focuses on two types of B-cell cancers: childhood B-cell acute lymphoblastic leukemia (B-ALL), and aggressive B-cell non-hodgkin s lymphoma (NHL)
More informationCost-effectiveness of sebelipase alfa (Kanuma ) for the treatment of lysosomal acid lipase (LAL) deficiency infantile paediatric adult
Cost-effectiveness of sebelipase alfa (Kanuma ) for the treatment of lysosomal acid lipase (LAL) deficiency The NCPE has issued a recommendation regarding the cost-effectiveness of sebelipase alfa (Kanuma
More informationA LOOK AT CGRP INHIBITORS FOR MIGRAINE PREVENTION JUNE 2018
JUNE 2018 Overview: About Migraine WHAT IS MIGRAINE? Migraine is a common, recurrent headache disorder that affects approximately 20% of women and 6-10% of men in the US. Migraine attacks are characterized
More informationVALUE FRAMEWORKS IN HTA Are Value Frameworks Useful in Helping Canadian Cancer Systems Determine Funding for New Therapies?
VALUE FRAMEWORKS IN HTA Are Value Frameworks Useful in Helping Canadian Cancer Systems Determine Funding for New Therapies? April 24, 2017 Background Therapeutic innovation continues to grow as new therapies
More informationEconomic Evaluation. Defining the Scope of a Costeffectiveness
Economic Evaluation Defining the Scope of a Costeffectiveness Analysis II This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes
More informationSetting The setting was not explicitly stated. The economic study was carried out in the UK.
Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK Beale S, Bagust A, Shearer A T, Martin A, Hulme L Record Status This is a critical abstract
More informationSeptember 2017 A LOOK AT PARP INHIBITORS FOR OVARIAN CANCER. Drugs Under Review. ICER Evidence Ratings. Other Benefits. Value-Based Price Benchmarks
September 2017 Drugs Under Review ICER s report reviewed the clinical effectiveness and value of olaparib (Lynparza, AstraZeneca), rucaparib (Rubraca, Clovis Oncology), and niraparib (Zejula, Tesaro),as
More informationNICE decisions on health care provisions in England
NICE decisions on health care provisions in England Matt Stevenson, Professor of Health Technology Assessment (HTA), ScHARR, University of Sheffield, UK A quick introduction I am Technical Director of
More informationAbout the National Centre for Pharmacoeconomics
Cost effectiveness of sofosbuvir (in combination with either ribavirin or pegylated interferon + ribavirin) (Sovaldi ) for the treatment of hepatitis C infection The NCPE has issued a recommendation regarding
More informationSetting The setting was outpatient, secondary care. The economic study was carried out in the UK.
An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK Palmer A J, Valentine W J, Ray J A, Foos V, Lurati F, Smith I, Lammert
More informationClinical and economic consequences of non-adherence
Clinical and economic consequences of non-adherence Mickaël Hiligsmann Maastricht University, CAPHRI Research Institute, the Netherlands, Department of Public Health Sciences, Belgium ESPACOMP 15 th Annual
More informationHealth Technology Assessment and the Demands of the Fourth Hurdle Experiences from TLV in Sweden
1 Health Technology Assessment and the Demands of the Fourth Hurdle Experiences from TLV in Sweden Ulf Persson IHE, The Swedish Institute for Health Economics & Institute of Economic Research, School of
More informationBackground 1. Comparative effectiveness of nintedanib
NCPE report on the cost effectiveness of nintedanib (Vargatef ) in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung
More informationSetting The setting was secondary care. The economic study appears to have been conducted in the UK.
One year comparison of costs of coronary surgery versus percutaneous coronary intervention in the stent or surgery trial Weintraub W S, Mahoney E M, Zhang Z, Chu H, Hutton J, Buxton M, Booth J, Nugara
More informationCost-effectiveness of cladribine (Mavenclad ) for the
Cost-effectiveness of cladribine (Mavenclad ) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features The NCPE has issued a recommendation
More informationSummary A LOOK AT ANTIANDROGEN THERAPIES FOR NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER CASTRATION-RESISTANT PROSTATE CANCER TREATMENT OPTIONS
A LOOK AT ANTIANDROGEN THERAPIES FOR NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER OCTOBER 2018 Summary CASTRATION-RESISTANT PROSTATE CANCER Prostate cancer is the second most common cause of cancer
More informationWhat do we mean by brand value (innovation) within the pharmaceutical sector? Biomedicine Master Program, Lund University, Sweden
What do we mean by brand value (innovation) within the pharmaceutical sector? Biomedicine Master Program, Lund University, Sweden Sunil Ramkali Account Director, W Communication Agency 11 th November 2014
More informationThe cost-effectiveness of screening blood donors for malaria by PCR Shehata N, Kohli M, Detsky A
The cost-effectiveness of screening blood donors for malaria by PCR Shehata N, Kohli M, Detsky A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationHealth Economic Assessment: Cost-Effectiveness Thresholds and Other Decision Criteria
Int. J. Environ. Res. Public Health 2010, 7, 1835-1840; doi:10.3390/ijerph7041835 Reply OPEN ACCESS International Journal of Environmental Research and Public Health ISSN 1660-4601 www.mdpi.com/journal/ijerph
More informationPersonalized Medicine*: a health economist s view
Personalized Medicine*: a health economist s view Lieven Annemans Ghent University Lieven.annemans@ugent.be * or stratified, or targeted, or precision,.. Grimbergen, November 2014 1 We need to stimulate
More informationIntroducing NCCN Academy for Excellence & Leadership in Oncology April Program Overview
Introducing NCCN Academy for Excellence & Leadership in Oncology April 2009 Program Overview In 2009, NCCN will launch the NCCN Academy for Excellence & Leadership in Oncology, a series of oncology certificate
More informationAn economic evaluation of rizatriptan in the treatment of migraine Thompson M, Gawel M, Desjardins B, Ferko N, Grima D
An economic evaluation of rizatriptan in the treatment of migraine Thompson M, Gawel M, Desjardins B, Ferko N, Grima D Record Status This is a critical abstract of an economic evaluation that meets the
More informationhe Case for QALY s: US Decision- Making for Pharmaceuticals Disadvantages? Christopher Leibman Sr. Director Pharmacoeconomics Elan Pharmaceuticals
he Case for QALY s: US Decision- Making for Pharmaceuticals Disadvantages? Christopher Leibman Sr. Director Pharmacoeconomics Elan Pharmaceuticals What s wrong with QALYs, they seem so nice? Apologies
More informationNonpharmacologic Interventions for Treatment-Resistant Depression. Public Meeting December 9, 2011
Nonpharmacologic Interventions for Treatment-Resistant Depression Public Meeting December 9, 2011 New England CEPAC Goal: To improve the application of evidence to guide practice and policy in New England
More informationSetting The setting was primary care. The economic study was carried out in the UK and the USA.
Cost-effectiveness of losartan-based therapy in patients with hypertension and left ventricular hypertrophy: a UK-based economic evaluation of the Losartan Intervention For Endpoint Reduction in Hypertension
More informationSetting The setting was secondary care. The economic analysis was conducted in Vancouver, Canada.
Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke Sinclair S E, Frighetto, Loewen P S, Sunderji R, Teal P, Fagan S C, Marra C A Record Status This is a critical abstract
More informationSetting The setting appears to have been secondary care. The economic study was conducted in the USA.
Cost-effectiveness of use of the GlucoWatch Biographer in children and adolescents with type 1 diabetes: a preliminary analysis based on a randomized controlled trial Eastman R C, Leptien A D, Chase H
More informationValue-based frameworks in oncology
28 November 2017 Value-based frameworks in oncology Clarity or confusion? Prepared for: European Statistical Meeting on Latest Trends in HTA Prepared by: Jan McKendrick, Senior Director PRMA Consulting
More informationUsing CEA to inform state policy 30 November 2017
E: jshoch@ucdavis.edu T: @j_hoch https://twitter.com/j_hoch USING COST- EFFECTIVENESS ANALYSIS TO INFORM STATE POLICY Health Policy and Management Jeffrey S. Hoch, PhD Associate Director, Center for Healthcare
More informationrosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.
rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationFINAL CDEC RECOMMENDATION
FINAL CDEC RECOMMENDATION APIXABAN (Eliquis Bristol-Myers Squibb Canada and Pfizer Canada Inc.) New Indication: Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation Recommendation:
More informationSummary 1. Comparative effectiveness of ponatinib
Cost-effectiveness of ponatinib (Iclusig ) as indicated for adult patients with: (i) CP-, AP-, or BP- chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to
More information